These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 8916730)

  • 1. Interferon beta in multiple sclerosis.
    Richards RG
    BMJ; 1996 Nov; 313(7066):1159. PubMed ID: 8916730
    [No Abstract]   [Full Text] [Related]  

  • 2. Use of interferon beta 1b for multiple sclerosis. Importance of relapses must not be underestimated.
    Cardy P
    BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939142
    [No Abstract]   [Full Text] [Related]  

  • 3. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.
    Forbes RB; Lees A; Waugh N; Swingler RJ
    BMJ; 1999 Dec; 319(7224):1529-33. PubMed ID: 10591710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of interferon-beta in multiple sclerosis stopped early.
    Bonn D
    Lancet; 1998 Feb; 351(9102):573. PubMed ID: 9492786
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of interferon beta 1b for multiple sclerosis. Manufacturer defends the drug.
    Longthorne PN
    BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939141
    [No Abstract]   [Full Text] [Related]  

  • 6. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
    Petkau J; White R
    Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
    [No Abstract]   [Full Text] [Related]  

  • 7. [Interferon-beta in multiple sclerosis--who is going to be treated?].
    Aarli JA
    Tidsskr Nor Laegeforen; 1999 Sep; 119(21):3114. PubMed ID: 10522472
    [No Abstract]   [Full Text] [Related]  

  • 8. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
    Rice G
    Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
    [No Abstract]   [Full Text] [Related]  

  • 9. Beta interferon and multiple sclerosis: why the fuss?
    Mumford CJ
    QJM; 1996 Jan; 89(1):1-3. PubMed ID: 8730337
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of multiple sclerosis with interferon beta-1 b.
    Abdul-Ahad A; Shah S; Galazka A
    Neurology; 1997 Aug; 49(2):641-2. PubMed ID: 9270626
    [No Abstract]   [Full Text] [Related]  

  • 11. Shortcomings in pharmacy benefit forecasting--interferon beta products.
    Rich SJ; Meyer C
    J Manag Care Pharm; 2003; 9(4):373; author reply 374. PubMed ID: 14613461
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of interferon beta 1b for multiple sclerosis. Patients will put up with side effects because of their desire to beat the disease.
    Chellingsworth M
    BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939140
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.
    Bryant J; Clegg A; Milne R
    BMJ; 2000 May; 320(7247):1474-5; author reply 1475-6. PubMed ID: 10877569
    [No Abstract]   [Full Text] [Related]  

  • 14. Why interferon beta 1b was licensed is a mystery.
    Harvey P
    BMJ; 1996 Aug; 313(7052):297-8. PubMed ID: 8704553
    [No Abstract]   [Full Text] [Related]  

  • 15. [Immunotherapy of multiple sclerosis. Consensus and controversies].
    Hohlfeld R
    Nervenarzt; 1999 Apr; 70(4):297. PubMed ID: 10354989
    [No Abstract]   [Full Text] [Related]  

  • 16. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.
    Blake G; Murphy S
    Neurology; 1997 Dec; 49(6):1747-8. PubMed ID: 9409387
    [No Abstract]   [Full Text] [Related]  

  • 17. Bad decision NICE.
    Ellis SJ
    Lancet; 2002 Feb; 359(9304):447. PubMed ID: 11844551
    [No Abstract]   [Full Text] [Related]  

  • 18. [A short history of beta-interferon therapy of multiple sclerosis].
    Stock G; Horowski R
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-utility analysis of interferon beta for multiple sclerosis.
    Parkin D; McNamee P; Jacoby A; Miller P; Thomas S; Bates D
    Health Technol Assess; 1998; 2(4):iii-54. PubMed ID: 9580870
    [No Abstract]   [Full Text] [Related]  

  • 20. Newer long-term treatments for multiple sclerosis.
    Pryse-Phillips W
    Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.